Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025

Reuters

Nov 18, 2025

Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025

Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current financial resources to fund operations into fiscal 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584567123"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584567123\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584567123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584567123","market":"fut","top_or_hot":-1,"title":"Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current financial resources to fund operations into fiscal 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENTA\">Enanta Pharmaceuticals Inc.</a> published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current financial resources to fund operations into fiscal 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENTA\">Enanta Pharmaceuticals Inc.</a> published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7vr2Np:1","article_id":"2584567123","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584567123","pubTimestamp":1763413363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current fin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"Enanta Pharmaceuticals公布2025财年净亏损8190万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":0.9},"content_text":"Enanta Pharmaceuticals posts $81.9 million net loss for fiscal 2025\n    \n\n        Enanta Pharmaceuticals reported a net loss of $18.7 million, or $0.87 per diluted common share, for the fourth quarter ended September 30, 2025, compared to a net loss of $28.8 million, or $1.36 per diluted common share, in the same period in 2024. For the full fiscal year 2025, the company recorded a net loss of $81.9 million, or $3.84 per diluted common share, down from a net loss of $116.0 million, or $5.48 per diluted common share, in fiscal year 2024. Cash, cash equivalents, and marketable securities totaled $188.9 million as of September 30, 2025. The company raised gross proceeds of $74.8 million from a public offering in October 2025. Enanta announced the development of EPS-3903, an oral STAT6 inhibitor, and EDP-978, an oral KIT inhibitor with plans to file an investigational new drug application in early 2026. The company also reported positive topline data from a Phase 2b study of Zelicapavir in high-risk adults with respiratory syncytial virus. Enanta expects its current financial resources to fund operations into fiscal 2029.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}